Y electrophoresis in a 1.5 agarose gel and bands were sequenced using the ABI Prism Dye Terminator Cycle Sequencing Kit (Perkin-Elmer, Beaconsfield, UK). To validate the isoforms nucleotide sequence, amplified products were purified through Sepharose (GE Healthcare, Waukesha, WI) and sequenced on both strands on an ABI Prism 3100 automated sequencer (PerkinElmer). PCR products were inserted into the mammalian expression vector pLENTI6/V5 Directional (KDM5A-IN-1 Invitrogen, Ltd, Paisley, UK), using manufacturer instructions, and incorporated into chemically competent TOP10 E. coli (Invitrogen). Transformed bacteria were grown overnight in ampicillin-supplemented LB-Agar (Applichem, Germany). Plasmid DNA from transformed E. coli cells was sequenced to check the orientation and nucleotide sequence for each CEBPB isoform. The human full-length CDH3-luciferase vector was generated by our group, as previously described [18]. Normalization pRLCMV Renilla Luciferase Control Reporter Vector was purchased to Promega (Promega Corporation, Madison, WI).ImmunohistochemistryDouble immunostaining for C/EBPb and P-cadherin was performed in 3 mm sections of 23 formalin-fixed paraffinembedded (FFPE) invasive breast carcinomas that have previously showed strong expression of 
both proteins, in order to illustrate their consistent cellular co-localization. Standard immunohistochemistry was performed as previously described [16]. For the reaction, we used the Envision G2 Double-stain (DakoCytomation, Glostrup, Denmark), according to manufacturer instructions. Specific conditions used for C/EBPb and P-cadherin are listed in Table S1. FFPE sections from normal breast gland, skin or normal gastric mucosa were used as positive controls for C/EBPb and Pcadherin. Negative controls were performed by replacing the primary antibody with PBS/non-immune serum. The present study was conducted under the national regulative law for the usage of biological specimens from tumour banks, where the samples are exclusively available for research purposes in the case of retrospective studies (National Regulative Law number 12/2005 ?I Serie-A, nu. 18?6th January, 2005).Materials and Methods AntibodiesThe buy Naringin following primary anti-human antibodies were used for 1081537 Western Blot and/or Immunohistochemistry against: P-cadherin (BD Transduction Biosciences, Lexington, KY), C/EBPb (Santa Cruz Biotechnology, CA), b-actin (Santa Cruz Biotechnology) and b-tubulin (Sigma-Aldrich, St. Louis, NO). Technical conditions are described in Table S1 (Supporting Information). Anti-mouse and anti-goat horseradish peroxidase-conjugated secondary antibodies were used for WB [HRP-conjugated, dilutions: 1:2000] (Santa Cruz Biotechnology). For chromatin immnunoprecipitation (ChIP) assays, the following antibodies were used: anti-C/EBPb (C-19, Santa Cruz Biotechnology), and two control IgGs (Active Motif, CA and Santa Cruz Biotechnology).Cell CultureHuman breast cancer cell line MCF-7/AZ was kindly provided by Prof. Marc Mareel (Ghent University, Belgium) [22], while BT20 cells were purchased to American Type Culture 16574785 Collection (ATCC, Manassas, VA). Cell lines were routinely maintained at 37uC, 5 CO2, in the following media (Invitrogen): 50 DMEM/50 HamF12 (MCF-7/AZ), or only DMEM (BT-20). All media contained 10 of heat-inactivated foetal bovine serum (Greiner Bio-one, Wemmel, Belgium), 100 IU/mL penicillin and 100 mg/mL streptomycin (Invitrogen).Promoter Vectors and cDNA ConstructsThe pLENTI-C/EBPb expression vectors.Y electrophoresis in a 1.5 agarose gel and bands were sequenced using the ABI Prism Dye Terminator Cycle Sequencing Kit (Perkin-Elmer, Beaconsfield, UK). To validate the isoforms nucleotide sequence, amplified products were purified through Sepharose (GE Healthcare, Waukesha, WI) and sequenced on both strands on an ABI Prism 3100 automated sequencer (PerkinElmer). PCR products were inserted into the mammalian expression vector pLENTI6/V5 Directional (Invitrogen, Ltd, Paisley, UK), using manufacturer instructions, and incorporated into chemically competent TOP10 E. coli (Invitrogen). Transformed bacteria were grown overnight in ampicillin-supplemented LB-Agar (Applichem, Germany). Plasmid DNA from transformed E. coli cells was sequenced to check the orientation and nucleotide sequence for each CEBPB isoform. The human full-length CDH3-luciferase vector was generated by our group, as previously described [18]. Normalization pRLCMV Renilla Luciferase Control Reporter Vector was purchased to Promega (Promega Corporation, Madison, WI).ImmunohistochemistryDouble immunostaining for C/EBPb and P-cadherin was performed in 3 mm sections of 23 formalin-fixed paraffinembedded (FFPE) invasive breast carcinomas that have previously showed strong expression of both proteins, in order to illustrate their consistent cellular co-localization. Standard immunohistochemistry was performed as previously described [16]. For the reaction, we used the Envision G2 Double-stain (DakoCytomation, Glostrup, Denmark), according to manufacturer instructions. Specific conditions used for C/EBPb and P-cadherin are listed in Table S1. FFPE sections from normal breast gland, skin or normal gastric mucosa were used as positive controls for C/EBPb and 
Pcadherin. Negative controls were performed by replacing the primary antibody with PBS/non-immune serum. The present study was conducted under the national regulative law for the usage of biological specimens from tumour banks, where the samples are exclusively available for research purposes in the case of retrospective studies (National Regulative Law number 12/2005 ?I Serie-A, nu. 18?6th January, 2005).Materials and Methods AntibodiesThe following primary anti-human antibodies were used for 1081537 Western Blot and/or Immunohistochemistry against: P-cadherin (BD Transduction Biosciences, Lexington, KY), C/EBPb (Santa Cruz Biotechnology, CA), b-actin (Santa Cruz Biotechnology) and b-tubulin (Sigma-Aldrich, St. Louis, NO). Technical conditions are described in Table S1 (Supporting Information). Anti-mouse and anti-goat horseradish peroxidase-conjugated secondary antibodies were used for WB [HRP-conjugated, dilutions: 1:2000] (Santa Cruz Biotechnology). For chromatin immnunoprecipitation (ChIP) assays, the following antibodies were used: anti-C/EBPb (C-19, Santa Cruz Biotechnology), and two control IgGs (Active Motif, CA and Santa Cruz Biotechnology).Cell CultureHuman breast cancer cell line MCF-7/AZ was kindly provided by Prof. Marc Mareel (Ghent University, Belgium) [22], while BT20 cells were purchased to American Type Culture 16574785 Collection (ATCC, Manassas, VA). Cell lines were routinely maintained at 37uC, 5 CO2, in the following media (Invitrogen): 50 DMEM/50 HamF12 (MCF-7/AZ), or only DMEM (BT-20). All media contained 10 of heat-inactivated foetal bovine serum (Greiner Bio-one, Wemmel, Belgium), 100 IU/mL penicillin and 100 mg/mL streptomycin (Invitrogen).Promoter Vectors and cDNA ConstructsThe pLENTI-C/EBPb expression vectors.
